Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Cardioprotection by volatile anesthetics. Vascul Pharmacol 2005 Apr-May;42(5-6):243-52

Date

06/01/2005

Pubmed ID

15922257

DOI

10.1016/j.vph.2005.02.005

Abstract

Preconditioning describes a very powerful endogenous mechanism by which the heart may be protected against ischemia and reperfusion injury. Transient administration of a volatile anesthetic before a prolonged ischemic episode reduces myocardial infarct size to a degree comparable to that observed during ischemic preconditioning. Many components of the signal transduction pathways responsible for cardioprotection are shared by anesthetic and ischemic preconditioning. Exposure to volatile anesthetics generates small "triggering" quantities of reactive oxygen species (ROS) by directly interacting with the mitochondrial electron transport chain or indirectly through a signaling cascade in which G-protein-coupled receptors, protein kinases, and mitochondrial ATP-sensitive potassium (K(ATP)) channels play important roles. Several clinical studies also suggest that preconditioning by volatile anesthetics exerts beneficial effects in patients undergoing cardiac surgery. This review summarizes some of the recent major developments in the understanding of cardioprotection by volatile anesthetics.

Author List

Bienengraeber MW, Weihrauch D, Kersten JR, Pagel PS, Warltier DC

Authors

Paul S. Pagel MD, PhD Professor in the Anesthesiology department at Medical College of Wisconsin
Dorothee Weihrauch DVM, PhD Professor in the Anesthesiology department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Anesthetics, Inhalation
Animals
Cardiotonic Agents
Humans
Ischemic Preconditioning, Myocardial
jenkins-FCD Prod-387 b0ced2662056320369de4e5cd5f21c218c03feb3